Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2-, and ABCC10-multidrug resistance xenograft models
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
A panel of clinically used tyrosine kinase inhibitors was compared and nilotinib was found to most potently sensitize specific anticancer agents by blocking the functions of ABCB1/P-glycoprotein, ABCG2/BCRP and ABCC10/MRP7 transporters involved in multi-drug resistance. Nilotinib appreciably enhanced the antitumor response of 1) paclitaxel in the ABCB1- and novel ABCC10-xenograft models, and 2) doxorubicin in a novel ABCG2-xenograft model. With no apparent toxicity observed in the above models, nilotinib attenuated tumor growth synergistically and increased paclitaxel concentrations in ABCB1-overexpressing tumors. The beneficial actions of nilotinib warrant consideration as viable combinations in the clinic with agents that suffer from MDR-mediated insensitivity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536 · cited 1×
“The overexpression of certain ABC transporters such as ABCB1 (Multiple Drug Resistance 1, Pglycoprotein), ABCC/MRP subfamily (Multidrug Resistance Protein) and ABCG2 (Breast Cancer Resistance Protein, MitoXantrone Resistance protein, ATP-Binding Cassette of Placenta) are significantly correlated with MDR in tumor cell…”
BackgroundMechanisms of Cancer Drug Resistance
Gottesman, M. M. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.103929 · Cited by 2,643 · cited 3×
“The overexpression of certain ABC transporters such as ABCB1 (Multiple Drug Resistance 1, Pglycoprotein), ABCC/MRP subfamily (Multidrug Resistance Protein) and ABCG2 (Breast Cancer Resistance Protein, MitoXantrone Resistance protein, ATP-Binding Cassette of Placenta) are significantly correlated with MDR in tumor cell…”
BackgroundStructure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding
Aller, S. G., Yu, J., Ward, A., Weng, Y., Chittaboina, S., Zhuo, R., Harrell, P. M., Trinh, Y. T., Zhang, Q., Urbatsch, I. L., et al. (2009) · Science · doi:10.1126/science.1168750 · Cited by 1,929 · cited 4×
“[31], and reported critical residues shown by site-directed mutagenesis experiments for ABCG2 [34; 35].”
BackgroundMethodInfluentialDeeley, R. G., Westlake, C., & Cole, S. P. C. (2006) · Physiological Reviews · doi:10.1152/physrev.00035.2005 · Cited by 761 · cited 1×
“Multidrug resistance (MDR) is characterized by energy-dependent efflux of drugs from cancer cells by ATP-binding cassette (ABC) transporters that may cause tumors to be insensitive to chemotherapy [1; 2].”
BackgroundDai, C.-L., Tiwari, A. K., Wu, C.-P., Su, X.-D., Wang, S.-R., Liu, D.-G., Ashby, C. R., Huang, Y., Robey, R. W., Liang, Y.-J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0499 · Cited by 386 · cited 7×
“The two perpendicular diameters of tumors (termed A and B) were recorded every 3rd day and tumor volume (V) was estimated according to the following formula published previously [7; 36]:”
BackgroundMethodInfluentialSelf-citation
Cited by
Kathawala, R. J., Gupta, P., Ashby, C. R., & Chen, Z.-S. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2014.11.002 · Cited by 777
Self-citationChen, Z., Shi, T., Zhang, L., Zhu, P., Deng, M., Huang, C., Hu, T., Jiang, L., & Li, J. (2016) · Cancer Letters · doi:10.1016/j.canlet.2015.10.010 · Cited by 729
Self-citationHolbeck, S. L., Camalier, R., Crowell, J. A., Govindharajulu, J. P., Hollingshead, M., Anderson, L. W., Polley, E., Rubinstein, L., Srivastava, A., Wilsker, D., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0489 · Cited by 359
Liu, X. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-13-7647-4_2 · Cited by 254
Krchniakova, M., Skoda, J., Neradil, J., Chlapek, P., & Veselska, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093157 · Cited by 61
“Supporting these findings, in in vivo experiments in respective xenograft mouse models, TKIs combined with conventional chemotherapeutics showed a gre ter inhibitory effect on tumor growth than single drugs [20,29,30].”
BackgroundInfluential
Metadata
- Authors
- Tiwari, A. K., Sodani, K., Dai, C.-L., Abuznait, A. H., Singh, S., Xiao, Z.-J., Patel, A., Talele, T. T., Fu, L., Kaddoumi, A., Gallo, J. M., & Chen, Z.-S.
- Venue
- Cancer Letters
- Publisher
- Elsevier BV
- Published
- 2013-01
- Volume
- 328
- Issue
- 2
- Pages
- 307-317
- ISSN
- 0304-3835 (ISSN-L)
- OpenAlex
- W2070791205
- Cited by
- 128
- References
- 5
- FWCI
- 5.54
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2-, and ABCC10-multidrug resistance xenograft models. https://app.cochat.ai/papers/10.1016/j.canlet.2012.10.001
- The paper
- Tiwari, A. K., Sodani, K., Dai, C.-L., Abuznait, A. H., Singh, S., Xiao, Z.-J., Patel, A., Talele, T. T., Fu, L., Kaddoumi, A., Gallo, J. M., & Chen, Z.-S. (2013). Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2-, and ABCC10-multidrug resistance xenograft models. Cancer Letters. https://doi.org/10.1016/j.canlet.2012.10.001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.